Analysis of image heterogeneity using 2D Minkowski functionals detects tumor responses to treatment
Article first published online: 25 FEB 2013
Copyright © 2013 Wiley Periodicals, Inc.
Magnetic Resonance in Medicine
Volume 71, Issue 1, pages 402–410, January 2014
How to Cite
Larkin, T. J., Canuto, H. C., Kettunen, M. I., Booth, T. C., Hu, D.-E., Krishnan, A. S., Bohndiek, S. E., Neves, A. A., McLachlan, C., Hobson, M. P. and Brindle, K. M. (2014), Analysis of image heterogeneity using 2D Minkowski functionals detects tumor responses to treatment. Magn Reson Med, 71: 402–410. doi: 10.1002/mrm.24644
- Issue published online: 17 DEC 2013
- Article first published online: 25 FEB 2013
- Manuscript Accepted: 24 DEC 2012
- Manuscript Revised: 11 DEC 2012
- Manuscript Received: 14 OCT 2012
- Cancer Research UK programme grant . Grant Number: C197/A3514
- Biotechnology and Biological Sciences Research Council . Grant Number: BB/E000266/1
- Medical Research Council UK; Royal College of Radiologists; Addenbrooke's CharitableTrust
- Minkowski functionals;
- image analysis
The acquisition of ever increasing volumes of high resolution magnetic resonance imaging (MRI) data has created an urgent need to develop automated and objective image analysis algorithms that can assist in determining tumor margins, diagnosing tumor stage, and detecting treatment response.
We have shown previously that Minkowski functionals, which are precise morphological and structural descriptors of image heterogeneity, can be used to enhance the detection, in T1-weighted images, of a targeted Gd3+-chelate-based contrast agent for detecting tumor cell death. We have used Minkowski functionals here to characterize heterogeneity in T2-weighted images acquired before and after drug treatment, and obtained without contrast agent administration.
We show that Minkowski functionals can be used to characterize the changes in image heterogeneity that accompany treatment of tumors with a vascular disrupting agent, combretastatin A4-phosphate, and with a cytotoxic drug, etoposide.
Parameterizing changes in the heterogeneity of T2-weighted images can be used to detect early responses of tumors to drug treatment, even when there is no change in tumor size. The approach provides a quantitative and therefore objective assessment of treatment response that could be used with other types of MR image and also with other imaging modalities. Magn Reson Med 71:402–410, 2014. © 2013 Wiley Periodicals, Inc.